Solventum's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Solventum in the third quarter 2026?
Solventum Corporation achieved a return on average equity (ROE) of 3.18 % in its third quarter 2026, which is below Solventum's average return on equity, which stands at 20.77%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Equipment & Supplies industry 10 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 384, from total ROE ranking in the second quarter 2026 at 389.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	-3.63 %	31.69 %	52.33 %	-56.72 %	-
Y / Y Net Income Change	-	2.22 %	-90.51 %	103.23 %	937.7 %
Net Income (TTM) in Millions	156	1,434	1,432	1,556	1,524
Return On Equity (TTM)	3.18 %	28.96 %	30.71 %	36.74 %	25.88 %
SOLV's Total Ranking	# 384	# 389	# 0	# 0	#
Equity (TTM) in Millions	4,805	4,800	4,969	5,049	4,986
Seq. Equity Change	0.1 %	-3.4 %	-1.58 %	1.26 %	36.79 %
Seq. Net Income Change	-	607.69 %	-79.37 %	-95.02 %	1306.67 %

Back to SOLV Management Effectiveness >> SOLV's 5 Years Annual ROE >> Compare SOLV ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 11
Sector	# 58
Overall	# 384

Return On Equity Statistics
High	Average	Low
36.74 %	20.77 %	6.98 %
(Dec 31 2025)		(Jun 30 2025)

SOLV Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Equity in Millions	5,049	11,666	0	0	0
Y / Y Equity Change	-56.72 %	-	-	-	-
Net Income in Millions	1,556	479	0	0	0
Y / Y Net Income Change	224.84 %	-	-	-	-
Return On Equity	30.82 %	4.11 %	-	-	-

Back to SOLV Management Effectiveness >> SOLV's 5 Years Annual ROE >> Compare SOLV ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 30.82 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SOLV's' Return on Equity at Yahoo Finance
SOLV's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SOLV's Competitors
Subscribers only: Roe for Solventum's Suppliers
Subscribers only: Return On Equity for SOLV's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Pacific Health Care Organization Inc	8.10 %
Incyte Corporation	7.08 %
Conmed Corporation	7.07 %
Teva Pharmaceutical Industries Limited	6.37 %
Integer Holdings Corporation	6.02 %
Avantor Inc	5.96 %
Ligand Pharmaceuticals Incorporated	5.22 %
Lifestance Health Group Inc	4.82 %
Jazz Pharmaceuticals Plc	4.62 %
Pfizer Inc	4.62 %
Innovage Holding Corp	4.52 %
Icu Medical Inc	2.81 %
Biogen Inc	1.86 %
Integra Lifesciences Holdings Corp	1.24 %

Date modified: 2026-11-08T13:46:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.